Abstract
BackgroundMass drug administration (MDA) with azithromycin is a cornerstone of the trachoma elimination strategy. Although the global prevalence of active trachoma has declined considerably, prevalence persists or even increases in some communities and districts. To increase understanding of MDA impact, we investigated the prevalence of active trachoma and ocular C. trachomatis prevalence, organism load, and circulating strains at baseline and one-year post-MDA in The Gambia and Senegal.MethodsPre- and one-year post-MDA, children aged 0–9 years were examined for clinical signs of trachoma in six Gambian and 12 Senegalese villages. Ocular swabs from each child’s right conjunctiva were tested for evidence of ocular C. trachomatis infection and organism load (ompA copy number), and ompA and multi-locus sequence typing (MLST) was performed.ResultsA total of 1171 children were examined at baseline and follow-up in The Gambia. Active trachoma prevalence decreased from 23.9% to 17.7%, whereas ocular C. trachomatis prevalence increased from 3.0% to 3.8%. In Senegal, 1613 and 1771 children were examined at baseline and follow-up, respectively. Active trachoma prevalence decreased from 14.9% to 8.0%, whereas ocular C. trachomatis prevalence increased from 1.8% to 3.6%. Higher organism load was associated with having active trachoma and severe inflammation. Sequence typing demonstrated that all Senegalese samples were genovar A, whereas Gambian samples were a mix of genovars A and B. MLST provided evidence of clustering at village and household levels and demonstrated differences of strain variant frequencies in Senegal, indicative of an “outbreak”. MLST, including partial ompA typing, provided greater discriminatory power than complete ompA typing.ConclusionsWe found that one round of MDA led to an overall decline in active trachoma prevalence but no impact on ocular C. trachomatis infection, with heterogeneity observed between villages studied. This could not be explained by MDA coverage or number of different circulating strains pre- and post-MDA. The poor correlation between active trachoma and infection prevalence supports the need for further work on alternative indicators to clinical signs for diagnosing ocular C. trachomatis infection. MLST typing has potential molecular epidemiology utility, including better understanding of transmission dynamics, although relationship to whole-genome sequence variability requires further exploration.
Highlights
Mass drug administration (MDA) with azithromycin is a cornerstone of the trachoma elimination strategy
To understand the reasons for variation in MDA impact in these two low prevalence countries at different programmatic stages, and since MDA is distributed annually, we aimed to investigate the one-year impact of a single MDA with azithromycin on active trachoma and ocular C. trachomatis prevalence, organism load, circulating strains and spatial distribution in The Gambia and Senegal
As a sub-study, we aimed to evaluate the relationship between multi-locus sequence typing (MLST) and whole-genome sequence (WGS) variation using a population from Bijagos Islands, Guinea-Bissau
Summary
Mass drug administration (MDA) with azithromycin is a cornerstone of the trachoma elimination strategy. Mass drug administration (MDA) with antibiotics is one component of the World Health Organization (WHO)-endorsed SAFE strategy for trachoma elimination: surgery for trichiasis; antibiotics to clear ocular Chlamydia trachomatis infection; and facial cleanliness and environmental improvement to reduce infection transmission [2]. Subsequent survey data demonstrated 0.3% ocular C. trachomatis infection but greater than 10% TF prevalence [5], suggesting The Gambia was on course for trachoma elimination. A 2004 study in the Nioro Department (within Kaolack Region, which had a prevalence of 6.8% in the 2000 survey), had an active trachoma prevalence of 17.4% in children aged 2–5 years [9]. These data demonstrated heterogeneity in active trachoma prevalence throughout the country
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.